OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
BEIJING, Feb. 08, 2016 -- BeiGene, Ltd. (“BeiGene” or “the Company”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced the closing of its initial public offering of 7,590,000 American Depositary Shares (“ADSs”), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS, before underwriting discounts. This includes the full exercise of the underwriters’ option to purchase additional ADSs. All of the ADSs in the offering were offered by BeiGene. The ADSs are listed on The NASDAQ Global Select Market under the ticker symbol “BGNE.”
Goldman, Sachs & Co., Morgan Stanley, and Cowen and Company acted as joint book-running managers. Baird acted as co-manager of the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 2, 2016. The offering was made only by means of a prospectus, copies of which may be obtained for free from the offices of Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050 [email protected]
